Figure 6.

CIP2A gene silencing mediated by 599 and its peptide variants in complex with siCIP2A

(A) Real-time PCR analysis of CIP2A mRNA levels in CAL 27 cancer cells 48 h post-treatment with siNT or siCIP2A in complex with either 599 or its peptide variants at 50:1 Peptide:siRNA molar (12.5 N/P) ratios. The CIP2A mRNA levels were normalized to endogenous 18S rRNA. Data are mean ± SEM of three independent samples, where ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and p ≥ 0.05 is not significant compared to 599 (Student’s t test). (B) Fold change in CIP2A silencing mediated by the 599 peptide variants normalized to 599. Data are mean ± SEM of three independent samples, where ∗∗p < 0.01, ∗∗∗p < 0.001, and p ≥ 0.05 is not significant (ns) compared to 599 (Student’s t test). (C) Western blot analyses of CIP2A protein expression levels in CAL 27 cancer cells 48 h post-treatment with siNT or siCIP2A in complex with either 599 or its peptide variants at 50:1 Peptide:siRNA molar (12.5 N/P) ratios. β-actin protein levels were monitored to ensure equal loading of samples.